Gaudium IVF and Women Health Limited (GAUDIUMIVF)
₹101.46 -1.28% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Gaudium IVF's revenue was ₹19.4 Cr (+9.1% year on year, -36.2% on the previous quarter), and net profit ₹1.8 Cr (-42.2% year on year); the operating margin was 12.5%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹19.4 | +9.1% | -36.2% |
| Operating profit | ₹2.4 | -52.9% | -80.1% |
| Net profit | ₹1.8 | -42.2% | -78.8% |
| EPS (₹) | 0.25 | -50.0% | -78.3% |
| Operating margin | 12.5% | — | — |
GAUDIUMIVF delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 57.34% of the GAUDIUMIVF shares traded on NSE were taken to delivery, against the stock's own 20-session average of 54.79%. That is close to its usual level. Turnover was only ₹94 lakh, so a handful of trades can move this figure. Volume was 0.4 times its average, well below normal.
Delivery in the last 5 sessions: 49.1% · 47.4% · 53.7% · 61.1% · 57.3%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Gaudium IVF and Women Health Limited concluded its 11th Annual General Meeting on September 28, 2026, passing all five proposed resolutions with over 99.9% majority approval. The voting covered the adoption of FY2026 financial statements, the reappointment of Non-Executive Director Mr. Vishad Khanna, and remuneration approvals for Dr. Peeyush Khanna (Whole-Time Director) and Dr. Manika Khanna (Chairperson & MD). Additionally, M/s Suresh Nainwal & Company was appointed as Secretarial Auditors for five consecutive years. A total of 54,408,001 votes were polled across 88 voting members, representing 74.75% of the total 72,786,884 equity shares.
- All 5 resolutions passed with more than 99.99% votes polled in favour.
- Total voter turnout was 74.7497%, with 54,408,001 votes cast out of 72,786,884 total shares.
- Promoter group cast 51,887,292 votes, accounting for 99.9921% of their holding and 100% in favour.
- Approval granted for the remuneration of Whole-Time Director Dr. Peeyush Khanna and CMD Dr. Manika Khanna.
- Appointment of M/s Suresh Nainwal & Company as Secretarial Auditor approved for 5 consecutive years.
Gaudium IVF and Women Health Limited has announced the closure of its trading window starting Thursday, October 01, 2026. The closure applies to designated persons and their immediate relatives in compliance with SEBI insider trading regulations. It will remain in effect until 48 hours after the declaration of unaudited standalone and consolidated financial results for the quarter and half-year ending September 30, 2026. The exact date of the board meeting to approve the results will be announced separately.
- Trading window closes effective Thursday, October 01, 2026
- Closure covers results for the quarter and half-year ending September 30, 2026
- Window to reopen 48 hours after the announcement of unaudited financial results
- Applicable to designated persons and their immediate relatives under SEBI PIT Regulations
Gaudium IVF and Women Health Limited has commenced commercial operations at its new IVF Centre/Hub in Gurgaon, Haryana, effective September 24, 2026. This launch is in line with the IPO objects stated in its Prospectus dated February 25, 2026. The centre is equipped with IVF and healthcare infrastructure, including its proprietary Gaudium Signature Lab. The addition expands the company's footprint beyond its Jun 2026 revenue base of Rs 19.38 crore.
- Commercial operations commenced at the new IVF Centre on September 24, 2026
- Expansion aligned with the IPO objects detailed in the Prospectus dated February 25, 2026
- Facility located at SCO No. 1, Second Floor, Old Judicial Complex, Civil Lines, Gurugram
- Company posted Rs 19.38 crore in revenue and Rs 1.78 crore in net profit in the recent Jun 2026 quarter
Gaudium IVF and Women Health Limited has dispatched physical letters containing the web-link and navigation path for the FY 2025-26 Annual Report to shareholders without registered email addresses. The company's 11th Annual General Meeting (AGM) is scheduled to be held on September 28, 2026, via Video Conferencing. The cut-off date to determine voting rights is September 21, 2026, with remote e-voting taking place between September 25 and September 27, 2026.
- 11th Annual General Meeting scheduled for Monday, September 28, 2026 at 02:00 PM IST via VC/OAVM
- Cut-off date for reckoning remote e-voting rights set as Monday, September 21, 2026
- Remote e-voting window runs from September 25, 2026 (09:00 AM IST) to September 27, 2026 (05:00 PM IST)
- Electronic copies dispatched on September 03, 2026 to registered shareholders
Gaudium IVF and Women Health Limited has issued the notice for its 11th Annual General Meeting scheduled for September 28, 2026, via Video Conferencing. Key ordinary items include the adoption of FY26 financial statements and director re-appointment by rotation. Special business items include revising the annual salary of Whole-Time Director Dr. Peeyush Khanna from ₹24 lakh to ₹48 lakh (plus ₹36 lakh consultancy fees) effective October 1, 2026, and ratifying ₹1.80 crore annual consultancy fees for Chairperson & MD Dr. Manika Khanna.
- 11th AGM scheduled to be held on Monday, September 28, 2026, at 2:00 PM IST via VC/OAVM
- Proposed doubling of base salary for Whole-Time Director Dr. Peeyush Khanna to ₹48,00,000 per annum (from ₹24,00,000 per annum) plus ₹36,00,000 per annum consultancy fees
- Approval/ratification of ₹1,80,00,000 per annum consultancy fees for MD Dr. Manika Khanna
- Shareholder cut-off date for dispatch of AGM notice was August 28, 2026
Gaudium IVF reported Q1 FY27 revenue growth of 9.1% YoY to ₹19.4 crore, with EBITDA of ₹2.4 crore and PAT of ₹1.8 crore, reflecting pre-investments for expansion. Management reiterated FY27 revenue growth guidance of 30% YoY. The company is executing its 19-centre IPO rollout plan, aiming for 10 new hubs in FY27 (South Extension operational, Gurgaon and Nagpur opening shortly) alongside international spokes in Paris, Nigeria, and Sydney.
- Q1 FY27 revenue increased 9.1% YoY to ₹19.4 crore, with EBITDA at ₹2.4 crore and PAT at ₹1.8 crore
- Management guided for 30% YoY revenue growth in FY27 with sustained EBITDA and PAT margins
- Targeting 10 new hubs in FY27 out of 19 planned IPO rollout centres; Gurgaon and Nagpur launching in August/September 2026
- Reported first-attempt pregnancy success rate at 62% and cumulative rate at 85%, supported by AI embryology tools SiD and ERICA
Gaudium IVF and Women Health Limited has informed exchanges that the audio recording of its earnings call for the quarter ended June 30, 2026 (Q1 FY27), held on August 14, 2026, is now available on its website. The disclosure is submitted pursuant to Regulation 30 and Regulation 46 of SEBI LODR Regulations. For context, the company reported revenue of ₹19.38 crore and net profit of ₹1.78 crore in the June 2026 quarter.
- Audio recording of Q1 FY27 earnings call uploaded on the company website on August 14, 2026
- Earnings call covered standalone and consolidated financial results for the quarter ended June 30, 2026
- Filing made under Regulation 30 and Regulation 46 of SEBI LODR Regulations, 2015
Gaudium IVF issued a revised Q1 FY27 investor presentation to correct EBITDA figures and disclose a one-time marketing expense of Rs 2.53 crore related to its AI tools, SID and ERICA. The consolidated adjusted EBITDA is now reported at Rs 5.33 crore with a 27.49% margin, while standalone adjusted EBITDA stands at Rs 5.08 crore (37.12% margin). The company reported Q1 FY27 revenue of Rs 19.38 crore, a decline from the Rs 24.51 crore reported in Dec 2025. Management highlighted an aggressive expansion plan to add 10 new hubs by FY29, starting with two in FY27.
- One-time marketing cost of Rs 253.24 lakhs incurred for AI tools SID and ERICA in Q1 FY27
- Consolidated Adjusted EBITDA corrected to Rs 532.75 lakhs, representing a 27.49% margin
- Average Revenue Per Patient (ARPP) reported at Rs 3.5 lakhs with a 62% first-attempt success rate
- Expansion roadmap includes 2 new hubs in FY27 (Delhi/NCR and Nagpur) and 8 hubs in FY28
- Revenue mix dominated by IVF treatments at 66.24%, followed by Pharmacy at 29.41%
Gaudium IVF reported Q1 FY27 revenue of Rs 19.38 cr, showing a moderation compared to the Dec 2025 quarter (Rs 24.51 cr) due to expansion-related costs. The company currently operates 8 hubs and 28 spokes across 9 states, with an average revenue per patient of Rs 3.5 lakhs. Profitability was impacted by investments in new hubs in Gurgaon and Nagpur and AI-led embryology tools, resulting in an adjusted EBITDA margin of 27.49%. Despite short-term margin pressure, the company maintains a high first-attempt success rate of 62%.
- Network consists of 8 Hubs and 28 Spokes across 9 Indian states as of August 2026.
- Average Revenue Per Patient (ARPP) is reported at Rs 3.5 lakhs.
- IVF treatment accounts for 66.24% of revenue, while Pharmacy contributes 29.41%.
- Adjusted EBITDA stood at Rs 5.33 cr with a margin of 27.49% for the period.
- India IVF market is projected to grow at a 13.1% CAGR to reach $4.54 billion by 2034.
Gaudium IVF reported Q1 FY27 revenue of ₹19.4 Cr, a 9.1% YoY increase, though profitability was significantly impacted by expansion activities. EBITDA fell 53% YoY to ₹2.4 Cr as margins compressed from 29% to 12.5% due to pre-operational costs for new hubs and clinical hiring. The company is executing a 19-centre expansion roadmap, with the South Extension hub already operational and a new ₹15 Cr hospital approved in Lucknow. Management indicates that excluding one-off expansion costs, EBITDA margins would have remained steady at approximately 27.6%.
- Revenue from operations grew 9.13% YoY to ₹19.38 Cr in Q1 FY27.
- EBITDA declined 52.96% YoY to ₹2.42 Cr due to front-loaded costs for the FY27 hub rollout.
- Board approved a new ₹15 Cr hospital in Lucknow, Uttar Pradesh, under a 30-year lease.
- Network currently stands at 8 hubs and 28 spokes with a 62% first-attempt pregnancy success rate.
- Expansion plan includes 10 hubs in FY27, 8 in FY28, and 1 in FY29 to reach a total of 19 new centres.
Gaudium IVF and Women Health Limited approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, during its board meeting on August 13, 2026. The company re-appointed Ram Rattan & Associates as Internal Auditor for FY 2026-27 and proposed Suresh Nainwal & Company as Secretarial Auditor for a five-year term. Additionally, the board reviewed the statement of deviation or variation under Regulation 32 regarding the utilization of fundraise proceeds. These actions represent standard quarterly compliance and governance updates.
- Approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026
- Re-appointed Ram Rattan & Associates as Internal Auditor for the Financial Year 2026-27
- Proposed appointment of Suresh Nainwal & Company as Secretarial Auditor for a 5-year term (FY 2026-27 to FY 2030-31)
- Reviewed the Statement of Deviation(s) or Variation(s) for fund utilization as per Regulation 32
Gaudium IVF and Women Health Limited reported a standalone revenue of ₹13.68 cr for Q1 FY27, a significant sequential decline from ₹22.17 cr in Q4 FY26. The company has successfully utilized ₹18.07 cr of its IPO proceeds to become debt-free as of June 30, 2026. Capital expenditure for new IVF centers is in the early stages, with only ₹1.03 cr spent out of the ₹50 cr allocated. Additionally, the board approved the appointment of M/s. Suresh Nainwal & Company as Secretarial Auditors for a five-year term.
- Q1 FY27 standalone revenue stood at ₹13.68 cr, down 38% from ₹22.17 cr in the previous quarter.
- Net profit for the quarter was ₹1.66 cr, compared to ₹7.73 cr in the preceding quarter ended March 2026.
- Utilized ₹18.07 cr to fully repay outstanding borrowings, achieving a debt-free status for the earmarked IPO objects.
- Only ₹1.03 cr (approx. 2%) of the ₹50 cr IPO allocation for new IVF centers has been deployed as of June 30, 2026.
- Reallocated ₹1.93 cr surplus from the debt repayment fund to General Corporate Purposes (GCP).
Gaudium IVF reported standalone revenue of ₹13.68 cr for Q1 FY27, representing an 11.5% YoY growth but a sharp 38% sequential decline from Q4 FY26. Net profit for the quarter stood at ₹1.66 cr, down significantly from ₹7.73 cr in the preceding quarter. The company has utilized only ₹1.03 cr of its ₹50 cr IPO capex budget for new IVF centers as of June 2026. Additionally, the board approved reallocating ₹1.93 cr of unspent debt repayment funds toward general corporate purposes after clearing all outstanding borrowings of ₹18.07 cr.
- Q1 FY27 revenue reached ₹13.68 cr, up 11.5% compared to ₹12.27 cr in Q1 FY26.
- Net profit dropped to ₹1.66 cr from ₹7.73 cr in the previous quarter (Q4 FY26).
- Only ₹1.03 cr (approx. 2%) of the ₹50 cr IPO allocation for new IVF centers has been utilized.
- Successfully repaid ₹18.07 cr in debt using IPO proceeds, making the company debt-free on those specific facilities.
- Appointed M/s. Suresh Nainwal & Company as Secretarial Auditor for a 5-year term (FY27-FY31).
Gaudium IVF reported a standalone revenue of ₹13.67 cr for Q1 FY27, a sequential decline from ₹22.16 cr in Q4 FY26. Net profit fell to ₹1.66 cr compared to ₹7.73 cr in the previous quarter, primarily due to higher 'other expenses' and lower operational income. A key positive is the utilization of ₹18.07 cr from IPO proceeds to clear all outstanding debt, making the company debt-free. However, execution on the planned ₹50 cr expansion for new IVF centers is slow, with only ₹1.03 cr deployed so far.
- Revenue from operations stood at ₹13.67 cr for the quarter ended June 30, 2026.
- Net profit decreased to ₹1.66 cr from ₹7.73 cr in the preceding quarter (March 2026).
- Completed repayment of ₹18.07 cr in borrowings using IPO proceeds, achieving zero-debt status.
- Only ₹1.03 cr utilized out of ₹50.00 cr earmarked for new IVF center establishment.
- Total IPO fresh issue proceeds of ₹90.00 cr saw a cumulative utilization of ₹34.03 cr by June 30, 2026.
Gaudium IVF and Women Health Limited has scheduled its earnings conference call for Friday, August 14, 2026, at 02:00 PM IST. The call will discuss the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Key management, including CMD Dr. Manika Khanna and CFO Rakesh K. Sharma, will be present to discuss performance. This follows a December 2025 quarter where the company reported a revenue of ‡24.51 cr and a net profit of ‡3.63 cr.
- Earnings conference call scheduled for August 14, 2026, at 02:00 PM IST
- Focus on financial results for the quarter ended June 30, 2026 (Q1 FY27)
- Management participation includes Chairperson & MD Dr. Manika Khanna and CFO Rakesh K. Sharma
- Company previously reported a Dec 2025 quarterly revenue of ‡24.51 cr
- Dial-in numbers provided for India, USA, UK, Hong Kong, and Singapore
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
